Stockholm, October 25 – Elekta announced today that Niklas Savander has been appointed as its next President and Chief Executive Officer, effective May 1, 2014. Niklas Savander will succeed Tomas Puusepp, who will continue with Elekta as a working member of its Board of Directors focusing on strategic matters and market-developments per the same date. […]
Study Data Shows Cialis 5 mg Initiated with Finasteride Provides Significantly Greater Improvements in Urinary Symptoms of Benign Prostatic Hyperplasia than Placebo with Finasteride INDIANAPOLIS, Oct. 25, 2013 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a product label addition for CIALIS to include data from a 26-week study that showed […]
SUNNYVALE, Calif., Oct. 24, 2013 (GLOBE NEWSWIRE) — In two independent analyses comparing robotic-assisted surgery and open surgery performed on patients with urologic cancers, researchers found that robotic-assisted surgery results in fewer overall complications during and after surgery, less blood loss and shorter length of hospital stay. In the first analysis, which was published in this month’s […]
One-time single eye injection of Jetrea® recognized as clinically and cost-effective treatment for eligible patients with vitreomacular traction, including macular hole Jetrea® is the first and only approved pharmacological treatment in the UK for this sight-threatening condition Vitreomacular traction with macular hole is an age-related eye condition that can cause loss of vision and impaired […]
INDIANAPOLIS, Oct. 23, 2013 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has assigned Priority Review to the regulatory submission for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy. “We are very pleased that the FDA has […]
Great Place to Work® recognizes Novartis for outstanding workplace culture Inclusion in list of best employers based on survey of 7,200 companies around the world Novartis ranked high for the pride associates take in their work, their teams and the organization Basel, October 22, 2013 – Novartis is pleased to announce that it has been […]
DUBLIN, Ohio, Oct. 15, 2013 — The Cardinal Health Surgical Clipper, which promotes perioperative safety combined with speed and simplicity, is now available. “Technology-enabled, evidence-based medicine can help improve quality, ensure safety and increase efficiencies,” said Shaden Marzouk, MD, vice president of Clinical Affairs at Cardinal Health, “and the Cardinal Health Surgical Clipper enables effective […]
California, USA, October 15, 2013 – Sandoz welcomes California Governor Jerry Brown’s veto of legislation that threatened to restrict patient access to biosimilars – high-quality follow-on versions of existing biologic medicines to treat complex disorders including cancer and autoimmune diseases. Mark McCamish, global head of Sandoz Biopharmaceutical Development, who wrote a personal letter to the governor […]
Omalizumab significantly reduced itch and hives caused by chronic spontaneous urticaria (CSU) as early as Week 1; benefit sustained over 24 weeks of active treatment[1] Omalizumab 300 mg was nearly twice as effective in improving patients’ quality of life within 12 weeks of treatment versus placebo[1] ASTERIA I is the final omalizumab CSU registration study […]
New four-year data showed that continued Gilenya treatment reduced brain volume loss by one third when compared to delaying Gilenya by two years. MS patients with higher rates of brain volume loss were more likely to experience disease progression. Patients who remained free of disease had consistently lower rates of brain volume loss compared to […]